When parents and physicians Drs Zachary and Geri Landman learned that their newborn daughter Lucy had an ultra-rare genetic condition, they were devastated.
In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus alliance with UK biotech Artios Pharma to develop precision medicines f
The world's largest database of cancer mutations can now be used to link mutations with drug treatments in what promises to be a step forward in precision oncology.